| Wehler, Thomas |
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC |
|
|
| Active, not recruiting | 4 | 34 | Europe | Afatinib, Osimertinib | Michael Hopp, Boehringer Ingelheim | Non-squamous NSCLC | 06/24 | 06/24 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
CaboRISE, NCT04522908: Dose Escalation Study of Cabozantinib for Advanced HCC Patients with Preserved Liver Function |
|
|
| Completed | 2 | 40 | Europe | Cabozantinib Oral Tablet, CABOMETYX | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan | Hepatocellular Carcinoma (HCC), Second Line Treatment | 10/24 | 10/24 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
| Completed | 2 | 92 | Europe | Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb, Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg | Pleural Mesothelioma Malignant | 01/25 | 01/25 | | |
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy |
|
|
| Not yet recruiting | 2 | 126 | Europe | bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich | Metastatic Gastro-esophageal Adenocarcinoma | 09/27 | 03/28 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
NCT04896931: New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC) |
|
|
| Recruiting | N/A | 200 | Europe | | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Biliary Tract Cancer, Neoadjuvant, Adjuvant and 1st Line | 09/29 | 09/29 | | |
